E

Biotech Strategy Blog Mailbag Monday

Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news

March 21, 2016
E

Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015
E

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015
E

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015
E

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015
E

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015
E

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015
E

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015
E

Mixed results with Macrogenics enoblituzumab at SITC

Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.

November 7, 2015
E

Did the epacadostat combo data disappoint at SITC?

Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?

November 7, 2015
E

SITC 2015 – what did we learn from the cancer immunotherapy workshops?

Review of the highlights from the SITC 2015 pre-meeting workshops

November 5, 2015
E

SITC 2015 International Cancer Immunotherapy Symposium

Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015

November 4, 2015
E

Preview of SITC 2015 Cancer Immunotherapy Meeting

Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.

November 3, 2015
E

CD40 as a Cancer Immunotherapy Target

Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.

November 3, 2015
E

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015
E

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015
E

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015